StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
1947.HK$0.59+5.36%
Fair $0.59+0.0%

1947.HK

Meihao Medical Group Co., Ltd

Healthcare / Medical Care FacilitiesHKSE

$0.59

+0.03 (+5.36%)

Fairly Valued+0.0%Fair Value $0.59Fund rank 27/100 · Data gapFallback financials|
SA 37/D
F-Score: 6/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 19%

FCF escenarios

weak_data · normalized FCF $51000.00 · quality 47.7/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 18/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

37/100

D

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -13.6%, below the 5% threshold
Thesis & Journal · 1947.HKLocal privado en este navegador · Meihao Medical Group Co., Ltd
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$354M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-13.6%

↓

Gross Margin

39.1%

↓

Debt/Equity

0.13

↓
52-Week Range$1
$0$1

TradingView lightweight chart

1947.HK price, volumen y niveles de valoración

Último $0.590Periodo -18.1%
Fair value: $0.590

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-7.2%

FCF CAGR

-36.9%

FCF margin

6.0%

FCF / Net income

-0.42x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $101.7M · net income $-14.3M · FCF $6.1M

2022-FY → 2025-FY

Gross margin

39.1%-22.3% pts

Operating margin

-20.1%-52.4% pts

Net margin

-14.1%-36.4% pts

FCF margin

6.0%-12.9% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$101.7M$101.7M$74.7M$73.5M$127.4M
Net Income$-14.3M$-14.3M$-32.4M$-13.6M$28.5M
EBITDA$-799000.00$-799000.00$-14.4M$8.7M$55.4M
EPS——-0.06-0.020.06
Gross Margin39.1%39.1%36.1%44.4%61.4%
Operating Margin-20.1%-20.1%-43.7%-14.8%32.4%
Net Margin-14.1%-14.1%-43.4%-18.5%22.3%
Balance Sheet
Debt/Equity0.130.130.280.200.21
Current Ratio2.152.15———
Cash Flow
Free Cash Flow$6.1M$6.1M$-20.0M$51000.00$24.1M
Returns
ROE-13.6%-13.6%-27.2%-8.2%16.0%
Valuation
P/E————9.32
EV/EBITDA———24.023.83
P/B3.353.351.761.581.50
Growth & Yield
Revenue Growth36.2%36.2%1.6%-42.3%—
EPS Growth——-145.4%-136.5%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +90.3%

Total return

+90.3%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.06 → n/d

Residual

+90.3%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+90.3%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.